Expression levels of NFAT2 and Lck show correlation with clinical outcome in CLL patients

被引：0
作者：
Heitmann, J. S. [1 ]
Fuchs, A. R. [1 ]
Mrklin, M. [2 ,3 ]
Kopp, H. -G. [1 ]
Quintanilla-Fend, L. [4 ]
Kanz, L. [1 ]
Rao, A. [5 ]
Wirths, S. [1 ]
Mueller, M. R. [1 ]
机构：
[1] Univ Klinikum Tubingen, Med Klin & Poliklin 2, Abt Hamatol Onkol Immunl Pulmol & Rheumatol, Tubingen, Germany
[2] German Canc Consortium DKTK, Tubingen, Germany
[3] Partnerstandort Tubingen, German Canc Res Ctr DKFZ, Tubingen, Germany
[4] Univ Klinikum Tubingen, Abt Pathol, Tubingen, Germany
[5] La Jolla Inst Allergy & Immunol, San Diego, CA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P526
引用
收藏
页码：140 / +
页数：2
相关论文
共 50 条
  • [11] Genetic Loss of NFAT2 Leads to CLL Transformation
    Maerklin, Melanie
    Heitmann, Jonas
    Truckenmueller, Felicia
    Kanz, Lothar
    Saur, Sebastian Jonas
    Ganser, Manuela
    Stefanie, Bugl
    Kopp, Hans-Georg
    Haap, Michael
    Rao, Anjana
    Wirths, Stefan
    Mueller, Martin R.
    BLOOD, 2015, 126 (23)
  • [12] Loss of NFAT2 leads to an acceleration of clonal evolution in CLL
    Mueller, D. J.
    Maerklin, M.
    Kanz, L.
    Wirths, S.
    Mueller, M. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 12 - 12
  • [13] Loss of NFAT2 Leads to an Acceleration of Clonal Evolution in CLL
    Mueller, David J.
    Maerklin, Melanie
    Kanz, Lothar
    Mueller, Martin R.
    Wirths, Stefan
    BLOOD, 2016, 128 (22)
  • [14] Inhibition of NFAT2 expression by FOXP3
    Cron, Randy Q.
    Torgerson, Troy R.
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S198 - S199
  • [15] Inhibition of NFAT2 expression by FOXP3
    Cron, Randy Q.
    Wells, Andrew D.
    Torgerson, Troy R.
    FASEB JOURNAL, 2008, 22
  • [16] Knock-down of the NFAT2 long and intermediate isoforms leads to CLL acceleration
    Heitmann, J. S.
    Maerklin, M.
    Truckenmueller, F. M.
    Fuchs, A. R.
    Kopp, H. -G
    Kanz, L.
    Rao, A.
    Wirths, S.
    Mueller, M. R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 12 - 12
  • [17] Knock-Down of the NFAT2 Long and Intermediate Isoforms Leads to CLL Acceleration
    Heitmann, Jonas S.
    Marklin, Melanie
    Anastasia, Posdorowkin
    Fuchs, Alexander R.
    Truckenmuller, Felicia M.
    Kopp, Hans-Georg
    Kanz, Lothar
    Rao, Anjana
    Wirths, Stefan
    Mueller, Martin R.
    BLOOD, 2016, 128 (22)
  • [18] Expression of the transcription factor NFAT2 in human neutrophils:: IgE-dependent, Ca2+- and calcineurin-mediated NFAT2 activation
    Vega, Antonio
    Chacon, Pedro
    Monteseirin, Javier
    El Bekay, Rajaa
    Alba, Gonzalo
    Martin-Nieto, Jose
    Sobrino, Francisco
    JOURNAL OF CELL SCIENCE, 2007, 120 (14) : 2328 - 2337
  • [19] High expression of NFAT2 contributes to carboplatin resistance in lung cancer
    Liu, Xi
    Pan, Chun-Guo
    Luo, Zhi-Qiang
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2019, 110
  • [20] Genetic loss of NFAT2 induces profound acceleration of CLL in the TCL1 mouse model
    Maerklin, M.
    Heitmann, J.
    Poljak, A.
    Worbs, D.
    Bugl, S.
    Kopp, H-G
    Kanz, L.
    Rao, A.
    Wirths, S.
    Mueller, M. R.
    ONKOLOGIE, 2013, 36 : 172 - 172
12345